TxCell

TxCell is a biopharmaceutical company located in Sophia-Antipolis, France, with 46 employees dedicated to the research, development, and production of T-cell immunotherapy-related drugs for the treatment of various inflammatory and autoimmune diseases. Currently, the company’s CAR-Treg candidate products under development are for treating transplant organ rejection (SOT - solid organ transplantation), LN - systemic lupus erythematosus, BP - pemphigus, and MS - multiple sclerosis.